Barcode Five Rights System



Use Barcode to prevent medication errors



ADERS ® is a barcode point of care, (BPOC), solution

Request Info











Practical Compliance Solutions, Corp. helps care facilities reduce risk at the patient's bedside. Our five rights barcode solution is the easiest to implement. Our barcode point of care system can help prevent medication errors in hospitals, long term care facilities, and assisted living communities.

ADERS ® is our barcode solution for the healthcare industry. It helps eliminate medication errors by allowing caregivers to scan NDC barcodes at the patient's bedside, verifying right patient, right drug, right time, right dose, and right route of administration. For more information click the products menu or send us a web request from our Contact menu. Ask for a DEMO CD. It is the full product that is licensed for an evaluation period.

We are offering a 30 day no-obligation free trial of the ADERS ® software. Care facilities can easily determine if ADERS ® is right for them by using the software as a pilot for a single unit or ward. Click here to download a Microsoft Project plan showing how you can implement a five rights point of care barcode pilot in less than a week. If you Don't own MS Project 2003, then here is a PDF copy just to see.... Download Adobe PDF Data Sheet

View a PowerPoint Presentation of ADERS ®.





Current Patient Safety and Drug Safety Updates from the FDA


FDA Press Releases RSS Feed

FDA Roundup: March 26, 2024
Tue, 26 Mar 2024 15:37:03 EDT

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Warns Consumers to Avoid Certain Topical Pain Relief Products Due to Potential for Dangerous Health Effects
Tue, 26 Mar 2024 14:31:45 EDT

  FDA warns consumers not to use certain over-the-counter pain relief products containing lidocaine that are marketed for topical use in cosmetic procedures like microdermabrasion, laser hair removal, tattooing and piercing, and issued warning letters to six companies for violating of federal law.

FDA Roundup: March 22, 2024
Fri, 22 Mar 2024 16:45:27 EDT

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Approves Nonsteroidal Treatment for Duchenne Muscular Dystrophy
Thu, 21 Mar 2024 18:29:46 EDT

  The FDA approved Duvyzat (givinostat) oral medication for the treatment of Duchenne Muscular Dystrophy (DMD) in patients six years of age and older. Duvyzat is the first nonsteroidal drug approved to treat patients with all genetic variants of DMD.

FDA Roundup: March 19, 2024
Tue, 19 Mar 2024 16:08:31 EDT

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Approves First Gene Therapy for Children with Metachromatic Leukodystrophy
Mon, 18 Mar 2024 13:52:03 EDT

  Lenmeldy is the first FDA-approved gene therapy indicated for the treatment of children with pre-symptomatic late infantile, pre-symptomatic early juvenile or early symptomatic early juvenile metachromatic leukodystrophy (MLD).

FDA Roundup: March 15, 2024
Fri, 15 Mar 2024 16:47:37 EDT

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease
Thu, 14 Mar 2024 15:58:34 EDT

  The FDA approved the first medication for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring, to be used along with diet and exercise.

FDA Roundup: March 12, 2024
Tue, 12 Mar 2024 15:54:41 EDT

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Seeks $7.2 Billion to Enhance Food Safety and Nutrition, Advance Medical Product Safety, and Strengthen Public Health
Mon, 11 Mar 2024 15:01:45 EDT

  FDA seeks $7.2 Billion to enhance food safety and nutrition, advance medical product safety, help support supply chain resiliency, strengthen the agency’s public-health and mission-support capacity, and modernize the FDA’s infrastructure, buildings, and facilities

FDA Roundup: March 8, 2024
Fri, 08 Mar 2024 15:26:03 EST

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight
Fri, 08 Mar 2024 13:59:11 EST

  The FDA approved a new use for a drug to reduce the risk of cardiovascular disease, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight.

FDA Takes Steps to Ensure Safety of Cinnamon Products Sold in the US
Wed, 06 Mar 2024 15:28:52 EST

  FDA takes additional steps to address concerns about elevated lead levels in cinnamon following the recent incident associated with certain cinnamon apple sauce pouches that resulted in lead poisoning in young children.

FDA Roundup: March 5, 2024
Tue, 05 Mar 2024 17:37:45 EST

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Clears First Over-the-Counter Continuous Glucose Monitor
Tue, 05 Mar 2024 16:21:57 EST

  Today, the U.S. Food and Drug Administration cleared for marketing the first over-the-counter continuous glucose monitor.

FDA Roundup: March 1, 2024
Fri, 01 Mar 2024 15:58:34 EST

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA, Industry Actions End Sales of PFAS Used in US Food Packaging
Wed, 28 Feb 2024 13:43:13 EST

  FDA announced that grease-proofing substances containing PFAS are no longer being sold by manufacturers for food contact use in the U.S. market. The completion of the voluntary market phase-out of these substances used on food packaging paper and paperboard, eliminates the primary source of dietary

FDA Roundup: February 27, 2024
Tue, 27 Feb 2024 15:58:26 EST

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Roundup: February 23, 2024
Fri, 23 Feb 2024 16:07:11 EST

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Roundup: February 20, 2024
Tue, 20 Feb 2024 17:10:20 EST

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Food and Drugs Administration--Recalls/Safety Alerts

Eugia US LLC (f/k/a AuroMedics Pharma LLC) Issues Voluntary Nationwide Recall of Methocarbamol Injection, USP 1000 mg/10 mL (100mg/mL) (Single Dose Vial) Due to Presence of White Particles
Thu, 28 Mar 2024 00:00:00 EDT

  East Windsor, New Jersey, Eugia US LLC (f/k/a AuroMedics Pharma LLC) has initiated a voluntary recall of lot number 3MC23011 of Methocarbamol Injection, USP 1000 mg/10 mL (100mg/mL) (Single Dose Vial) - 10mL Vial to the consumer level due to a customer product complaint for the presence of white par

Amneal Pharmaceuticals, LLC. Issues a Nationwide Voluntary Recall of Vancomycin Hydrochloride for Oral Solution USP, 250mg/5mL, Due to the Potential for Some Bottles to be Super Potent Which May be Harmful
Wed, 27 Mar 2024 18:29:00 EDT

  Amneal Pharmaceuticals, LLC. Bridgewater, New Jersey (Amneal), is voluntarily recalling 4 lots (see table below) of Vancomycin Hydrochloride for Oral Solution, USP, 250 mg/5mL packaged in 80 mL, 150 mL, or 300 mL pack sizes, to the Consumer Level. Some bottles may have been overfilled which can res

Roland Foods, LLC Recalls Roland® Tahini (100% Ground Sesame Seeds) 16 oz. Because of Possible Health Risk
Mon, 25 Mar 2024 16:08:00 EDT

  Roland Foods, LLC (“Roland Foods”) of New York, New York is recalling a specific production code of Roland® Tahini (100% Ground Sesame Seeds) 16 oz. because it has the potential to be contaminated with Salmonella, an organism which can cause serious and sometimes fatal infections in young children,

Voluntary Removal Announcement for the InfuTronix Nimbus Ambulatory Infusion Pump System
Wed, 20 Mar 2024 16:27:00 EDT

  InfuTronix, LLC has announced a voluntary recall of the Nimbus Ambulatory Infusion Pump System, including Nimbus II PainPro, Nimbus II Flex, Nimbus II Plus, Nimbus II EpiD and Nimbus II EMS from the US Market due to a high number (3698) of customer complaints related to the Nimbus Infusion Pump sys

Pyramid Wholesale Issues Recall of Various Brands of Products Sold as Dietary Supplements for Sexual Enhancement Because They Contain Undeclared Prescription Drugs Including Sildenafil (Viagra) and/or Tadalafil (Cialis)
Tue, 19 Mar 2024 13:31:00 EDT

  Pyramid Wholesale is issuing a recall of various brands of products sold as dietary supplements for sexual enhancement because they contain undeclared prescription drugs including Sildenafil (Viagra) and/or Tadalafil (Cialis).

Wenders LLC Recalls Trader Joes Nuts – 50% Less Sodium Roasted & Salted Whole Cashews Because of Possible Health Risk
Sun, 17 Mar 2024 00:00:00 EDT

  Wenders LLC of Dublin, CA is recalling specific production lots of Trader Joes Nuts – 50% Less Sodium Roasted & Salted Whole Cashews – (SKU Number – 37884) Lot# T12139, T12140, T12141, and T12142 because they have the potential to be contaminated with Salmonella, an organism which can cause serious

Kick Ash Products Issues Allergy Alert on Undeclared Almonds in Product
Thu, 14 Mar 2024 00:00:00 EDT

  Kick Ash Products of Ellison Bay, WI is recalling Door County Love Dark Chocolate Cherry Granola with Lot #061241, because it may contain undeclared ALMONDS. People who have an allergy or severe sensitivity to almonds run the risk of serious or life-threatening allergic reaction if they consume the

Par Pharmaceutical Issues Voluntary Nationwide Recall of One Lot of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution
Tue, 12 Mar 2024 14:53:00 EDT

  Endo International plc announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), is voluntarily recalling one lot of Treprostinil Injection 20mg/20mL (1mg/mL) to the consumer level. The product is being recalled due to the potential for the presence of silicone particulate

John B. Sanfilippo & Son, Inc Issues Allergy Alert on Undeclared Coconut and Milk in Great Value Honey Roasted Cashews 8.25 Oz
Tue, 12 Mar 2024 00:00:00 EDT

  John B. Sanfilippo & Son, Inc (JBSS) announced today it is voluntarily recalling a limited amount of 8.25 oz Great Value Honey Roasted Cashews, because it may contain undeclared coconut and milk. People who have an allergy or severe sensitivity to coconut or milk run the risk of serious or life-thre

Wesco, Inc. Issues Voluntary Recall and Allergy Alert on Undeclared Peanut in Wesco Mint No Bake Cookie Bites
Fri, 08 Mar 2024 00:00:00 EST

  Wesco, Inc. of Muskegon, MI is recalling 750 units of Wesco Mint No Bake Cookie Bites, because it may contain undeclared peanut. People who have an allergy or severe sensitivity to peanuts run the risk of serious or life-threatening allergic reaction if they consume these products. The affected Wesc

Stonewall Kitchen Issues Allergy Alert for Wheat in Limited Quantity of Gluten Free Cinnamon Sugar Doughnut Mix
Thu, 07 Mar 2024 00:00:00 EST

  Stonewall Kitchen of York, Maine is voluntarily recalling a limited amount of their Gluten Free Cinnamon Sugar Doughnut Mix because it may contain an undeclared allergen, wheat. People who have an allergy or severe sensitivity to wheat (which contains gluten) may risk serious allergic reaction if t

El Chilar Rodriguez LLC. Issues Voluntary Recall of El Chilar Ground Cinnamon “Canela Molida” Due to Elevated Lead Levels
Wed, 06 Mar 2024 18:00:00 EST

  El Chilar Rodriguez LLC of Apopka, FL is recalling 127 cases (12 bags/case) of El Chilar Ground Cinnamon “Canela Molida” (1.25 oz bag), because it may contain traces of lead.

Colonna Brothers, Inc. Issues a Voluntary Recall for “1.5oz Marcum Ground Cinnamon & 2.25oz Supreme Tradition Ground Cinnamon” Because of Possible Health Risk Due to Elevated Lead Levels
Wed, 06 Mar 2024 17:10:00 EST

  Colonna Brothers of North Bergen, NJ is recalling its 1.5oz Marcum Ground Cinnamon & 2.25oz Supreme Tradition Ground Cinnamon because of a possible health risk due to elevated lead levels. Short term exposures to very low levels of lead may not elicit any symptoms. It is possible that increased bloo

Expanded Press Release – Kalo Foods, LLC Recalls Single Slice Carrot Cake and Chocolate Cake Due to Undeclared Soy Allergen
Wed, 06 Mar 2024 11:00:00 EST

  KALO Foods, LLC is recalling Single Slice Carrot Cake UPC 8 53407 00418 4 and Single Slice Chocolate Cake UPC 8 53407 00418 4 due to a undeclared soy.

La Fiesta Food Products Recalls Cinnamon Ground Because of Possible Health Risk
Wed, 06 Mar 2024 00:00:00 EST

  La Fiesta Food Products, La Mirada California is recalling Cinnamon Ground .87oz because it has the potential to be contaminated with lead. Short term exposures to very low levels of lead may not elicit any symptoms. It is possible that increased blood lead levels may be the only apparent sign of le

Raja Foods Skokie, IL Is Recalling “Swad Brand Cinnamon Powder 3.5OZ Retail Packs” for Possible Lead Contamination
Wed, 06 Mar 2024 00:00:00 EST

  Raja Foods LLC of Skokie, Il is recalling its 3.5 ounce package of "SWAD CINNAMON POWDER" because it has the potential to be contaminated with lead.

Kalo Foods, LLC Recalls Single Slice Carrot Cake Due to Undeclared Soy Allergen
Tue, 05 Mar 2024 17:25:00 EST

  KALO Foods, LLC is recalling Single Slice Carrot Cake UPC 8 53407 00418 4 due to a undeclared soy. Although the package is labeled Carrot Cake, the ingredient panel and UPC Code is for their Chocolate Cake. The Carrot Cake contains soy which is not listed in the ingredient statement. People who hav

Sleepnet Corporation Issues Worldwide Recall of CPAP and BIPAP Masks with Magnets Due to Potential Interference with Certain Medical Implants
Fri, 01 Mar 2024 00:00:00 EST

  Hampton, NH – On March 1, 2024, Sleepnet Corporation initiated a worldwide recall for all CPAP and BIPAP masks with magnets due to potential interference with certain medical devices. When a magnet comes into close proximity to certain medical implants or metallic implants, it could interfere with t

Aji Mori Sauce Corp. DBA Sushi Koo Issues Voluntary Recall of Chillimami Sauce
Thu, 29 Feb 2024 00:00:00 EST

  Aji Mori Sauce Corp. DBA Sushi Koo of Los Angeles, CA, is voluntarily recalling its CHILLIMAMI SAUCE because product was manufactured and distributed without the California Department of Public Health (CDPH) Cannery Program oversight, making them just susceptible to contamination with Clostridium bo

Megadyne Reiterates Intended Use Population Change for Megadyne Mega Soft Universal and Universal Plus Patient Return Electrodes
Thu, 29 Feb 2024 00:00:00 EST

  Megadyne issued a Class 1 Medical Device Correction to hospitals to limit the use of MEGA SOFT Universal and Universal Plus Reusable Patient Return Electrodes to patients aged 12 years or older after receiving reports of adult and pediatric patient burns following surgical procedures in which MEGA S

What's New: Drugs RSS Feed

Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research Guidance for Industry
Thu, 28 Mar 2024 16:25:37 EDT

  Guidance for Industry;
Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research


CDER Manual of Policies & Procedures | MAPP
Thu, 28 Mar 2024 15:29:56 EDT

  CDER's Manual of Policies and Procedures (MAPPs) are federal directives and documentation of internal policies and procedures.

Drug Trials Snapshots: LITFULO
Thu, 28 Mar 2024 14:56:20 EDT

  Drug Trials Snapshots: LITFULO

Drug Trials Snapshots: POMBILITI
Thu, 28 Mar 2024 14:54:39 EDT

  Drug Trials Snapshots: POMBILITI

What's New Related to Drugs
Thu, 28 Mar 2024 14:50:41 EDT

  Want to know what's new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.

Novel Drug Approvals for 2023
Thu, 28 Mar 2024 14:46:08 EDT

  Each year, CDER approves a wide range of new drugs and biological products.

Integrated Safety Analyses in Drug Marketing Applications: Avoiding Common Mistakes - 03/07/2024
Thu, 28 Mar 2024 10:33:41 EDT

  Integrated Safety Analyses in Drug Marketing Applications: Avoiding Common Mistakes

Clinical Pharmacology Considerations for Antibody-Drug Conjugates Guidance for Industry
Thu, 28 Mar 2024 09:53:11 EDT

  Clinical Pharmacology

Expanding Generic Drug Access Through International Engagements - 02/28/2024
Thu, 28 Mar 2024 09:26:34 EDT

  Expanding Generic Drug Access Through International Engagements

Eugia US LLC (f/k/a AuroMedics Pharma LLC) Issues Voluntary Nationwide Recall of Methocarbamol Injection, USP 1000 mg/10 mL (100mg/mL) (Single Dose Vial) Due to Presence of White Particles
Thu, 28 Mar 2024 08:49:13 EDT

  East Windsor, New Jersey, Eugia US LLC (f/k/a AuroMedics Pharma LLC) has initiated a voluntary recall of lot number 3MC23011 of Methocarbamol Injection, USP 1000 mg/10 mL (100mg/mL) (Single Dose Vial) - 10mL Vial to the consumer level due to a customer product complaint for the presence of white par

Emergency Use Authorizations for Drugs and Non-Vaccine Biological Products
Thu, 28 Mar 2024 08:46:10 EDT

  Emergency Use Authorizations for Drugs and Non-Vaccine Biological Products

Gastrointestinal Drugs Advisory Committee Roster
Thu, 28 Mar 2024 07:09:40 EDT

  This page contains the Gastrointestinal roster, which lists the current members and the current number of vacancies for the committee.

Medical Imaging Drugs Advisory Committee Roster
Thu, 28 Mar 2024 07:03:19 EDT

  This page contains the Medical Imaging Drugs Advisory Committee roster, which lists the current members and the current number of vacancies for the committee.

Amneal Pharmaceuticals, LLC. Issues a Nationwide Voluntary Recall of Vancomycin Hydrochloride for Oral Solution USP, 250mg/5mL, Due to the Potential for Some Bottles to be Super Potent Which May be Harmful
Wed, 27 Mar 2024 18:55:14 EDT

  Amneal Pharmaceuticals, LLC. Bridgewater, New Jersey (Amneal), is voluntarily recalling 4 lots (see table below) of Vancomycin Hydrochloride for Oral Solution, USP, 250 mg/5mL packaged in 80 mL, 150 mL, or 300 mL pack sizes, to the Consumer Level. Some bottles may have been overfilled which can res

FDA Warns Consumers to Avoid Certain Topical Pain Relief Products Due to Potential for Dangerous Health Effects
Wed, 27 Mar 2024 16:14:44 EDT

  FDA warns consumers not to use certain over-the-counter pain relief products containing lidocaine that are marketed for topical use in cosmetic procedures like microdermabrasion, laser hair removal, tattooing and piercing, and issued warning letters to six companies for violating of federal law.

CDERLearn Training and Education
Wed, 27 Mar 2024 15:31:29 EDT

  Continuing Education and Training opportunities for healthcare professionals, academia, students and consumers.

Special Features
Wed, 27 Mar 2024 15:14:40 EDT

  Special Features links to articles, podcasts, etc

Over-The-Counter Monograph Drug User Fee Program (OMUFA)
Wed, 27 Mar 2024 14:18:46 EDT

  A user fee program for nonprescription (over-the-counter or OTC) monograph drugs would be a potential funding mechanism to supplement congressional non user-fee appropriations.

CDER Scientific Review Documents Supporting Emergency Use Authorizations for Drug and Biological Therapeutic Products | COVID-19
Wed, 27 Mar 2024 13:48:02 EDT

  CDER Scientific Reviews Supporting EUA for Therapeutic Products

Newly Added Guidance Documents
Wed, 27 Mar 2024 13:40:57 EDT

  Guidance documents represent the FDA's current thinking on a particular subject. New guidance documents are listed here for three months.

Whats New Vaccines Blood Biologics RSS Feed

Vaccines and Related Biological Products Advisory Committee March 5, 2024 Meeting Announcement - 03/05/2024
Thu, 28 Mar 2024 13:22:37 EDT

  This is the main page for the Vaccines and Related Biological Products Advisory Committee (VRBPAC) March 5, 2024 Meeting announcement and meeting materials.

Clinical Pharmacology Considerations for Antibody-Drug Conjugates Guidance for Industry
Thu, 28 Mar 2024 09:53:11 EDT

  Clinical Pharmacology

What’s New for Biologics
Wed, 27 Mar 2024 15:13:43 EDT

  Latest news from the Center for Biologics Evaluation and Research

CDER Scientific Review Documents Supporting Emergency Use Authorizations for Drug and Biological Therapeutic Products | COVID-19
Wed, 27 Mar 2024 13:48:02 EDT

  CDER Scientific Reviews Supporting EUA for Therapeutic Products

Blood Products Advisory Committee May 9, 2024 Meeting Announcement - 05/09/2024
Wed, 27 Mar 2024 13:41:21 EDT

  This is the main page for the Blood Products Advisory Committee May 9, 2024 Meeting Announcement and meeting materials.

Reducing Threats to the Blood Supply from West Nile Virus, Dengue Virus, and Chikungunya Virus Through Development of Detection Tools and Studies of Genetic Evolution and Pathogenesis
Tue, 26 Mar 2024 16:35:38 EDT

  A description of Maria Rios's research program and related publications.

Improving the Safety of Blood and Blood Related Products by Reducing the Risk of Transfusion-Transmission of Leishmania Parasites
Tue, 26 Mar 2024 16:25:52 EDT

  A description of Hira Nakhasi's research program and related publications.

Pathogenesis and Diagnosis of Hepatitis A Virus and Other Biodefense Agents
Tue, 26 Mar 2024 16:21:03 EDT

  A description of Gerardo Kaplan's research program and related publications.

Advanced Technology for Reducing the Risk of Transmission by Transfusion
Tue, 26 Mar 2024 16:10:55 EDT

  OBRR performs regulatory evaluation of in vitro diagnostic devices used to screen for infectious microorganisms in blood donations.

Studies to Evaluate Blood Safety: Risk of Transmission of Parasites such as Trypanosoma cruzi through Blood Transfusion
Tue, 26 Mar 2024 16:03:35 EDT

  A description of Alain Debrabant's research program and related publications.

Keeping Blood and Blood Products Safe by Developing Tests for Malaria and Other Parasites and Helping to Develop Malaria Vaccine
Tue, 26 Mar 2024 15:58:28 EDT

  A description of Sanjai Kumar's research program and related publications.

Drugs@FDA Data Files
Tue, 26 Mar 2024 15:50:41 EDT

  Drugs@FDA Downloadable Data File in ZIP format, Data Definitions, and Entity Relationship Diagram (ERD)

FDA Roundup: March 26, 2024
Tue, 26 Mar 2024 15:37:03 EDT

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Diagnosis and Pathogenesis of Hepatitis Viruses That Impact the Safety of Blood and Related Products
Tue, 26 Mar 2024 15:33:30 EDT

  David R. McGivern's research project "Diagnosis and Pathogenesis of Hepatitis Viruses That Impact the Safety of Blood and Related Products".

Improving Safety of the Blood Supply from Transmission of HIV/AIDS and Other Emerging Blood Borne Viral and Biodefense Agents by Developing Sensitive Diagnostic Tools and Investigating Disease Pathogenesis
Tue, 26 Mar 2024 15:03:37 EDT

  A description of Indira Hewlett's research program and related publications.

Ex Vivo Stored Blood Component Safety and Quality: Evaluation of Novel Methods for Pathogen Reduction and Functional Regulation in Blood Components
Tue, 26 Mar 2024 14:56:09 EDT

  A description of C. D. Atreya's research program and related publications.

Investigation of Potential Toxic Effects of Engineered Nanoparticles and Biologic Microparticles in Blood and Their Biomarker Applications
Tue, 26 Mar 2024 14:50:16 EDT

  A description of Jan Simak's research program and related publications.

Studies on Safety and Efficacy of Platelets and Other Transfused Blood Products
Tue, 26 Mar 2024 14:34:56 EDT

  A description of J.G. Vostal's research program and related publications.

Vascular-Based Biomarkers For Evaluation of Biological Product Safety and Efficacy
Tue, 26 Mar 2024 14:29:00 EDT

  The main focus of this research program is to study the mechanisms by which biological products or pathogens alter the functioning or integrity of the vascular system in both vascular endothelial cell culture systems and animal models.

Evaluating the Safety and Efficacy of Hemoglobin-based Blood Substitutes
Tue, 26 Mar 2024 14:10:33 EDT

  The development of a safe and effective blood substitute would greatly improve the emergency treatment of accident victims and wounded soldiers, as well as patients undergoing cardiac surgery, especially when whole blood is in short supply.





See how to prevent medication errors with bar codes using ADERS. Get your free pilot started today.





 
 

Contact Us


Corporate Headquarters


Practical Compliance Solutions
One Orient Way
Suite F156
Rutherford, NJ 07070
  201-728-8809


40.827731 N 74.101029 W

Connect With Us

   
 
 
© 2002 - 2024 - Copyright Practical Compliance Solutions - All rights reserved